Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria Differentiated profile of ALY-301 designed to enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results